Authors
Shaveta Vinayak, Sara M Tolaney, Lee Schwartzberg, Monica Mita, Georgia McCann, Antoinette R Tan, Andrea E Wahner-Hendrickson, Andres Forero, Carey Anders, Gerburg M Wulf, Patrick Dillon, Filipa Lynce, Corrine Zarwan, John K Erban, Yinghui Zhou, Nathan Buerstatte, Julie R Graham, Sujata Arora, Bruce J Dezube, Melinda L Telli
Publication date
2019/8/1
Journal
JAMA oncology
Volume
5
Issue
8
Pages
1132-1140
Publisher
American Medical Association
Description
Importance
Poly(adenosine diphosphate–ribose) polymerase inhibitor and anti–programmed death receptor-1 inhibitor monotherapy have shown limited clinical activity in patients with advanced triple-negative breast cancer (TNBC).
Objective
To evaluate the clinical activity (primary) and safety (secondary) of combination treatment with niraparib and pembrolizumab in patients with advanced or metastatic TNBC.
Design, Setting, and Participants
This open-label, single-arm, phase 2 study enrolled 55 eligible patients with advanced or metastatic TNBC irrespective ofBRCAmutation status or programmed death-ligand 1 (PD-L1) expression at 34 US sites. Data were collected from January 3, 2017, through October 29, 2018, and analyzed from October 29, 2018, through February 27, 2019.
Interventions
Patients were administered 200 mg of oral niraparib once daily in combination with 200 mg of intravenous …
Scholar articles
S Vinayak, SM Tolaney, L Schwartzberg, M Mita… - JAMA oncology, 2019